Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable ...

Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' ...

The company expects to save an additional $1.2 billion from automation, AI and other digital tools.

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pharma giant now looking for $7.7bn in annual savings by 2027 as it grapples with falling post-Covid sales and lack of new ...

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to a lower rate of COVID-19 infections in the U.S. and a drop in purchases by governments. To be sure ...